CD8A and neoplasm: Immunogenomic profiling analysis on tumor samples from TOPACIO trial showed mutational signature 3 as a surrogate of homologous recombination deficiency (HRD) and a positive immune score reflecting interferon-primed CD8-exhausted effector T-cells in a tumor microenvironment, and both of them were identified as determinants of response to niraparib plus pembrolizumab combination therapy (92).